NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $66.65 -0.95 (-1.41%) Closing price 04:00 PM EasternExtended Trading$66.20 -0.45 (-0.68%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bright Minds Biosciences Stock (NASDAQ:DRUG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DRUG alerts:Sign Up Key Stats Today's Range$65.18▼$69.4250-Day Range$59.17▼$90.2452-Week Range$24.00▼$123.75Volume320,841 shsAverage Volume353,862 shsMarket Capitalization$648.50 millionP/E RatioN/ADividend YieldN/APrice Target$143.83Consensus RatingModerate Buy Company Overview Bright Minds Biosciences Inc., trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments. The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders. Its second program, BMB-103, is in preclinical development targeting neuroinflammation and neuronal survival pathways relevant to Alzheimer’s disease. Bright Minds Biosciences operates research facilities in Vancouver and Montreal, collaborating with academic institutions and industry partners to advance its pipeline through both early-stage and later-stage clinical studies. Founded in 2020, Bright Minds completed its initial public listing to support ongoing research and development activities. The company’s leadership team includes experienced researchers, medicinal chemists and clinical development experts committed to translating cutting-edge neuroscience into scalable therapies. By focusing on small-molecule alternatives to traditional biologics, Bright Minds Biosciences seeks to offer patients oral treatments with favorable safety profiles and broad commercial applicability. AI Generated. May Contain Errors. Read More Bright Minds Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreDRUG MarketRank™: Bright Minds Biosciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 538th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingBright Minds Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialBright Minds Biosciences has a consensus price target of $143.83, representing about 115.8% upside from its current price of $66.65.Amount of Analyst CoverageBright Minds Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Bright Minds Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($4.90) to ($8.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bright Minds Biosciences is -27.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bright Minds Biosciences is -27.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBright Minds Biosciences has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bright Minds Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.65% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 1.34, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bright Minds Biosciences has recently increased by 1.49%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBright Minds Biosciences does not currently pay a dividend.Dividend GrowthBright Minds Biosciences does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Bright Minds Biosciences this week, compared to 3 articles on an average week. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bright Minds Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,785,124.00 in company stock.Percentage Held by Insiders42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bright Minds Biosciences' insider trading history. Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRUG Stock News HeadlinesBright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 6 at 5:08 AM | americanbankingnews.comBright Minds Biosciences (NASDAQ:DRUG) Upgraded by Wall Street Zen to "Sell" RatingJuly 4 at 1:18 AM | americanbankingnews.comAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion to AI infrastructure in 2026 alone - more than the entire dot-com buildout combined. When Zuckerberg told investors 'we want to make sure we're not underinvesting,' veteran Wall Street analyst Chris Rowe says that wasn't a growth pitch - it was fear. That money flows downstream through chipmakers, network builders, and small data infrastructure companies most investors have never heard of. Rowe spent 30 years tracking institutional money before it moves, and he says this spending won't stop regardless of market conditions - none of these four can afford to be the one who blinked.July 6 at 1:00 AM | True Market Insiders (Ad)Bright Minds Biosciences to Present at Jefferies Global Healthcare ConferenceMay 26, 2026 | globenewswire.comWhy a $5 Million New Position Signals Confidence in This Epilepsy Drug PipelineMay 21, 2026 | finance.yahoo.comJefferies initiates coverage of Bright Minds Biosciences (DRUG) with buy recommendationApril 14, 2026 | msn.comWhat Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?March 25, 2026 | insidermonkey.comBright Minds Biosciences to Present at Upcoming ConferencesFebruary 25, 2026 | globenewswire.comSee More Headlines DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $78.04 at the beginning of 2026. Since then, DRUG shares have decreased by 14.6% and is now trading at $66.65. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) posted its quarterly earnings data on Wednesday, May, 20th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.06. When did Bright Minds Biosciences' stock split? Bright Minds Biosciences's stock reverse split on Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bright Minds Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include HubSpot (HUBS), Blink Charging (BLNK), ConocoPhillips (COP), Netflix (NFLX), SoFi Technologies (SOFI). Company Calendar Last Earnings5/20/2026Today7/06/2026Next Earnings (Estimated)8/13/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 DRUG's financial health is in the Green zone, according to TradeSmith. DRUG has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRUG CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployeesN/AYear Founded2019Price Target and Rating Average Price Target for Bright Minds Biosciences$143.83 High Price Target$220.00 Low Price Target$80.00 Potential Upside/Downside+115.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.58% Return on Assets-20.25% Debt Debt-to-Equity RatioN/A Current Ratio81.47 Quick Ratio81.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.33 per share Price / Book8.00Miscellaneous Outstanding Shares9,730,000Free Float5,580,000Market Cap$648.50 million OptionableNot Optionable Beta-5.34 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:DRUG) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | Sponsored“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
